Cerus Co. (NASDAQ:CERS) SVP Carol Moore sold 26,684 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $3.59, for a total transaction of $95,795.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of NASDAQ:CERS traded up $0.43 during trading on Thursday, reaching $4.47. The company had a trading volume of 837,382 shares, compared to its average volume of 2,274,683. The company has a fifty day moving average of $4.66 and a two-hundred day moving average of $4.51. The stock has a market capitalization of $624.34 million, a P/E ratio of -8.60 and a beta of 1.19. Cerus Co. has a 12 month low of $2.71 and a 12 month high of $6.64. The company has a current ratio of 2.55, a quick ratio of 2.16 and a debt-to-equity ratio of 1.01.
Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.01). The company had revenue of $20.92 million during the quarter, compared to the consensus estimate of $20.90 million. Cerus had a negative return on equity of 112.64% and a negative net margin of 95.44%. As a group, equities research analysts predict that Cerus Co. will post -0.44 earnings per share for the current year.
CERS has been the topic of a number of research analyst reports. BTIG Research initiated coverage on shares of Cerus in a report on Wednesday, February 26th. They issued a “buy” rating and a $7.00 price target on the stock. BidaskClub lowered shares of Cerus from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Zacks Investment Research raised shares of Cerus from a “sell” rating to a “hold” rating in a report on Wednesday, March 18th. Finally, ValuEngine raised shares of Cerus from a “hold” rating to a “buy” rating in a report on Friday, January 3rd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $7.33.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Featured Article: What are high-yield dividend stocks?
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.